دورية أكاديمية
أعرض في EDS

A comparative analysis of clinical outcomes between conversion to mTOR inhibitor and calcineurin inhibitor reduction in managing BK viremia among kidney transplant patients.

التفاصيل البيبلوغرافية
العنوان: A comparative analysis of clinical outcomes between conversion to mTOR inhibitor and calcineurin inhibitor reduction in managing BK viremia among kidney transplant patients.
المؤلفون: Cho A; Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea., Park S; Department of Surgery, Samsung Medical Center, Seoul, South Korea., Han A; Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea., Ha J; Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea., Park JB; Department of Surgery, Samsung Medical Center, Seoul, South Korea., Lee KW; Department of Surgery, Samsung Medical Center, Seoul, South Korea., Min S; Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea. surgeonmsi@gmail.com.
المصدر: Scientific reports [Sci Rep] 2024 Jun 04; Vol. 14 (1), pp. 12855. Date of Electronic Publication: 2024 Jun 04.
نوع المنشور: Journal Article; Comparative Study
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Kidney Transplantation*/adverse effects , BK Virus* , Calcineurin Inhibitors*/therapeutic use , Viremia*/drug therapy , Polyomavirus Infections*/drug therapy , Tacrolimus*/therapeutic use , TOR Serine-Threonine Kinases*/antagonists & inhibitors , TOR Serine-Threonine Kinases*/metabolism , Immunosuppressive Agents*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Adult ; Viral Load/drug effects ; Treatment Outcome ; Tumor Virus Infections/drug therapy ; Tumor Virus Infections/virology ; Graft Rejection/drug therapy ; Graft Rejection/prevention & control ; Sirolimus/therapeutic use ; Republic of Korea ; Retrospective Studies ; Aged
مستخلص: BK virus-associated nephropathy (BKVAN) exerts a substantial impact on allograft survival, however, the absence of robust clinical evidence regarding treatment protocols adds to the complexity of managing this condition. This study aimed to compare the two treatment approaches. The study population consisted of patients who underwent kidney transplantation between January 2016 and June 2020 at two tertiary hospitals in Korea. Patients diagnosed with BK viremia were evaluated based on their initial viral load and the treatment methods. The 'Reduction group' involved dose reduction of tacrolimus while the 'Conversion group' included tacrolimus discontinuation and conversion to sirolimus. A total of 175 patients with an initial viral load (iVL) ≥ 3 on the log10 scale were evaluated within two iVL intervals (3-4 and 4-5). In the iVL 4-5 interval, the Reduction group showed potential effectiveness in terms of viral clearance without statistically significant differences. However, within the iVL 3-4 interval, the Reduction group demonstrated superior viral clearance and a lower incidence of biopsy-proven acute rejection (BPAR) than the Conversion group. The renal function over 12 months after BKV diagnosis showed no statistically significant difference. Reducing tacrolimus compared to converting to mTORi would be a more appropriate treatment approach for BK viral clearance in kidney transplantation. Further research is warranted in a large cohort of patients.
(© 2024. The Author(s).)
References: Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1321-1336. (PMID: 28576905)
Transplant Direct. 2017 Mar 10;3(4):e142. (PMID: 28405598)
J Clin Invest. 2023 Jan 17;133(2):. (PMID: 36378537)
Viruses. 2021 Mar 16;13(3):. (PMID: 33809472)
Am J Transplant. 2016 Mar;16(3):821-32. (PMID: 26639422)
Lancet Infect Dis. 2003 Oct;3(10):611-23. (PMID: 14522260)
Clin Transplant. 2019 Sep;33(9):e13528. (PMID: 30859620)
Am J Transplant. 2007 Dec;7(12):2727-35. (PMID: 17908275)
Transplantation. 2009 Apr 15;87(7):1019-26. (PMID: 19352121)
Transplantation. 2007 Jul 15;84(1):83-8. (PMID: 17627242)
Clin J Am Soc Nephrol. 2008 Mar;3 Suppl 2:S68-75. (PMID: 18309005)
Nephrol Dial Transplant. 2019 Jul 1;34(7):1240-1250. (PMID: 30476254)
Lancet. 1971 Jun 19;1(7712):1253-7. (PMID: 4104714)
Am J Transplant. 2005 Mar;5(3):582-94. (PMID: 15707414)
J Clin Med. 2022 Dec 08;11(24):. (PMID: 36555909)
Transplantation. 2004 Oct 15;78(7):1069-73. (PMID: 15480176)
Clin Transplant. 2013 Jul-Aug;27(4):546-54. (PMID: 23758330)
Am J Transplant. 2010 Dec;10(12):2615-23. (PMID: 21114642)
Am J Transplant. 2010 Jun;10(6):1401-13. (PMID: 20455882)
Nature. 2009 Jul 2;460(7251):108-12. (PMID: 19543266)
J Nephropathol. 2016 Jan;5(1):1-7. (PMID: 27047803)
Am J Transplant. 2016 Jul;16(7):2117-38. (PMID: 26990455)
N Engl J Med. 2002 Aug 15;347(7):527-30. (PMID: 12181409)
المشرفين على المادة: 0 (Calcineurin Inhibitors)
WM0HAQ4WNM (Tacrolimus)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
0 (Immunosuppressive Agents)
W36ZG6FT64 (Sirolimus)
EC 2.7.1.1 (MTOR protein, human)
تواريخ الأحداث: Date Created: 20240604 Date Completed: 20240604 Latest Revision: 20240612
رمز التحديث: 20240613
مُعرف محوري في PubMed: PMC11150265
DOI: 10.1038/s41598-024-60695-2
PMID: 38834615
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا